Ruxolitinib for Cancer Cachexia
Early Phase 1
Active, not recruiting
NCT04906746
| Condition | Stage IV Non-small Cell Lung Cancer, Cachexia |
|---|
| Phase | Early Phase 1 |
|---|
| Sponsor | Tu Dan |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 10 participants |
|---|
| Interventions | Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. |
|---|
| Start date | Feb 23, 2022 |
|---|
| Completion date | Sep 27, 2024 |
|---|
| Results posted | Jul 7, 2026 |
|---|
Summary
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
Number of Non-small Cell Lung Cancer Cachexia Patients With Toxicity With the Use of Ruxolitinib
3 months · Participants
| Ruxolitinib 10mg | 0 Participants |
|---|
| Ruxolitinimb 15mg | 0 Participants |
|---|
| Ruxolitinib 10mg | 0 Participants |
|---|
| Ruxolitinimb 15mg | 0 Participants |
|---|
| Ruxolitinib 10mg | 2 Participants |
|---|
| Ruxolitinimb 15mg | 2 Participants |
|---|
Number of Non-small Cell Lung Cancer Cachexia Patients With Toxicity With the Use of Ruxolitinib
3 months · Participants
| Intervention Arm- Received Ruxolitinib | 0 Participants |
|---|
| Intervention Arm- Received Ruxolitinib | 0 Participants |
|---|
Analysis of Any Preliminary Evidence Suggesting That Ruxolitinib Suppresses Adipose and Lean Muscle Loss in Cancer Cachexia Patients
4 months · Participants
| 10 mg Ruxolitinib | 2 Participants |
|---|
| 15mg Ruxolitinib | 2 Participants |
|---|
| 10 mg Ruxolitinib | 0 Participants |
|---|
| 15mg Ruxolitinib | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.